
Unmet Needs and Practice-Changing Takeaways
Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute names durability as the outstanding unmet need in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), since patients are not cured and most eventually progress, and says he is watching bispecific strategies combining PD-1 and VEGF inhibition closely.
Episodes in this series

Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute names durability as the outstanding unmet need in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), since patients are not cured and most eventually progress, and says he is watching bispecific strategies combining PD-1 and VEGF inhibition closely. Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center suggests those data may identify a subset exquisitely sensitive to immunotherapy. Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute says the open questions are which regimen to start with, how to sequence afterward, where antibody-drug conjugates fit, and what resistance will look like. For a single practice-changing point, Dr Gumbleton says nearly every patient needs an intensified regimen up front, and Dr Devarakonda says clinicians should get comfortable managing skin toxicity rather than removing an effective option from the toolkit.
Related to this article








